Advancements in Treating Cystic Fibrosis ~ A New Drug
September 10 ~ Written By Annanya VenkatCystic Fibrosis victims have been fighting an uphill battle for decades, but a beacon of hope seems to be shining through at last. Cystic Fibrosis (CF), an inherited and deadly mutative disorder that causes damage to the lungs and digestive system, has completely uprooted the lives of over 40 thousand Americans since 2020. However, the recent development of the experimental drug, Trikafta, has been proven to be capable of treating and curing CF cases that were formerly thought to be incurable (ScienceDaily).
Through the course of today’s blog, I will highlight several attributes, advancements, and potential drawbacks associated with the drug Trikafta. We will explore the alternative treatment options available for CF patients and what makes them different from Trikafta.
Trikafta is a groundbreaking drug used to treat cystic fibrosis, and is the first “triple combination therapy” readily available to treat patients. Trikafta has been approved for patients ages 12 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (FDA). 90% of patients with cystic fibrosis are expected to benefit graciously from the drug (KU Medical Center).
Attributes and Advancements:
Effective for Most CF Patients: Trikafta has shown remarkable effectiveness in treating CF. It is designed to address the underlying cause of the disease by targeting specific genetic mutations, specifically the F508del mutation and certain other mutations in the CFTR gene (National Library of Medicine). This allows it to benefit a larger percentage of CF patients compared to previously used drugs and treatments.
Improved Lung Function: The main danger most CF patients experience is regarding their lungs. Subsequently, taking Trikafta has proven to significantly decrease this danger. Many patients experience significant improvements in lung function when taking Trikafta. This can lead to better breathing, fewer respiratory infections, and an overall enhanced quality of life. (FDA)
Enhanced Nutrient Absorption: CF can heavily affect the digestive system, leading to malabsorption of the necessary nutrients. Trikafta can help improve nutrient absorption, leading to better weight gain, maintenance, and growth in some patients (Stanford Children’s Health).
Reduced Need for Other Therapies: Some patients on Trikafta may find they can reduce or eliminate the need for other CF treatments and therapies, such as nebulized medications or chest physiotherapy. This specifically removes a heavy load off of patients since having prolonged treatments and medications can cause severe fatigue to the patient (Stanford Children’s Health).
Extended Life Expectancy: Trikafta has the potential to significantly increase the life expectancy of CF patients, which is a major advancement in the treatment of this disease (FDA).
Potential Drawbacks:
High Cost: One of the most significant drawbacks of Trikafta is its high cost. The drug is extremely expensive, making it inaccessible for some patients, even with access to insurance coverage.
Not Effective for All Mutations: While Trikafta is effective for a substantial percentage of CF patients, it is not a universal cure. It only targets specific genetic mutations, so it may not benefit those with different mutations.
Long-term Safety: As Trikafta is a relatively new drug, its long-term safety and efficacy are still being studied. Continuous monitoring is essential to assess its impact over time.
Access and Equity: Access to Trikafta may be limited in some regions or countries, which raises issues of equity and disparities in healthcare access. Not all patients may have the means to access Trikafta since it is still largely in its preliminary stages of experimentation.
Resistance and Disease Progression: Some patients may develop resistance to Trikafta over time, and the disease can still progress despite treatment, especially in cases with advanced lung damage.
Alternative treatment options:
Airway Clearance Techniques (ACTs): This form of treatment involves physical methods to help loosen and clear mucus from the airways. Examples include: chest physiotherapy, percussion and postural drainage, and high-frequency chest wall oscillation devices (KU Medical Center). These are very commonly used techniques to cure CF or prolong the life expectancy of patients suffering from CF.
Bronchodilators: These medications help relax and open the airways, making it easier to breathe. They are often used as part of a comprehensive treatment plan for CF-related lung disease (Mayo Clinic). Bronchodilators are only a part of a whole when it comes to medicating CF patients, which can often take a heavy toll on the physical health of some CF patients (NHS Inform).
Antibiotics: CF patients are prone to lung infections, so antibiotics are frequently used to treat and prevent infections. They can be administered orally, intravenously, or through inhalation (Cleveland Clinic).
Lung Transplant: In cases of advanced lung diseases caused by CF, a lung transplant may be considered as a treatment option (Stanford Children’s Health). It can provide a new lease on life for some patients and significantly increase the life expectancy for many CF patients.
Clinical Trials: Participation in clinical trials for new CF therapies and treatments may be an option for some patients, especially those with unique mutations or treatment-resistant forms of the disease (Cystic Fibrosis Foundation). Just like Trikafta, new drugs and treatment opportunities are constantly presented to patients, some that could potentially save their lives.
Of all the advancements in modern medicine, the development of Trikafta for the treatment of cystic fibrosis stands as a symbol of scientific ingenuity and dedication to improving the lives of individuals living with this complex genetic disorder. However, as with any medical breakthrough, challenges remain, such as accessibility, long-term safety, and the ongoing pursuit of effective treatments for all CF mutations. Despite these hurdles, Trikafta serves as a beacon of hope, not only for those currently battling cystic fibrosis but for the continued progress and innovation that may one day lead to a world where CF is no longer a life-limiting condition.
References
https://www.sciencedaily.com/releases/2021/07/210719110521.htm
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266292/
https://www.goodrx.com/trikafta/what-is
https://www.mayoclinic.org/diseases-conditions/cystic-fibrosis/diagnosis-treatment/drc-20353706
https://my.clevelandclinic.org/health/diseases/9358-cystic-fibrosis